Skip to content

Role of MRS in Brain Lesions

Diagnostic Yield of Preoperative Magnetic Resonance Spectroscopy for Solitary Intra-axial Brain Lesion in Comparison to Histopathology

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05565690
Enrollment
64
Registered
2022-10-04
Start date
2022-10-01
Completion date
2024-11-01
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Lesion (General), Mrs

Brief summary

Aim of the study is evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm

Detailed description

The annual global age-standardized incidence of primary malignant brain tumors is \ 3.7 per 100,000 for males and 2.6 per 100,000 for females . Rates appear to be higher more in developed countries (males, 5.8 and females, 4.1 per 100,000) than in less developed countries (males 3.0 and females 2.1 per 100,000). More than half of all brain tumors are Intraparenchymal . Diagnosis of brain lesions and other focal intracranial lesions based on imaging methods alone is still facing a challenging problem. Accurate diagnosis is fundamentally vital for clinical management in patients with brain tumors. CT and standard MRI are the first line imaging modalities in evaluation of brain lesions; however, it does not always provide more precise details and characterization of the lesions whether it is benign or malignant. Conventional imaging techniques do not provide exact information about vascularity, cellularity and metabolism of the mass lesion . Magnetic Resonance Spectroscopy (MR Spectroscopy) is one of the tools used to determine themolecular structures of compounds or to detect the compound presence. MR Spectroscopy provides metabolic information from living tissues. The major brain metabolites detected are choline, creatine, N-acetyl aspartate (NAA), lactate, myoinositol, glutamine, glutamate, lipids and the amino acids leucine and alanine. Brain lesions show abnormal values of these metabolites as compared to normal tissue.Our study aims to determine the accuracy of MRS in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm, Discriminating neoplastic from non-neoplastic brain lesions is extremely necessary since a misdiagnosis can lead to a severe effect on neurosurgery and exposure to toxic chemotherapy or radiotherapy, which may cause damage to brain tissues.

Interventions

DEVICEMRS

It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* patients with solitary intraaxial brain lesions * patients with de novo lesions * Patient age : any age

Exclusion criteria

* patients with multiple intra-axial brain lesions * patients with extra-axial brain lesions * patients with recurrent lesions * patients receiving chemotherapy or radiotherapy * patients unfit for surgery

Design outcomes

Primary

MeasureTime frameDescription
evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasmBaselineAnalysis of the MRS metabolites peaks and test if they can differentiate between neoplastic and non neoplastic lesions and grades of neoplasm by comparison with postoperative histopathology

Contacts

Primary ContactAhmed Mohamed Aboelmagd, Resident doctor
ahmed.14223789@med.aun.edu.eg01099474580
Backup ContactMohamed El-Sayed Mahmoud, Professor
msmluxor@aun.edu.eg01016077797

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026